The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
First-line treatment locally advanced or metastatic oesophageal or gastroesophageal junction carcinoma that is not amenable to surgical resection or definitive CRT in combination with platinum- and fluoropyrimidine-based ChT
Gastrointestinal Cancers
Oesophageal or gastroesophageal carcinoma
HER2- GEJ (all randomized)
KEYNOTE-590
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Pembrolizumab
Cisplatin and 5-FU
Placebo + cisplatin and 5-FU
First-line treatment locally advanced unresectable or metastatic carcinoma of the oesophagus or HER2-negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥10
Gastrointestinal Cancers
Oesophageal or gastroesophageal carcinoma
HER2- PD-L1 CPS ≥10
KEYNOTE-590
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Pembrolizumab
Cisplatin and 5-FU ChT
Placebo + cisplatin and 5-FU ChT
First-line treatment
Gastrointestinal Cancers
Oesophageal or gastroesophageal carcinoma
HER2- GEJ (squamous cell)
KEYNOTE-590
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Pembrolizumab
Cisplatin and 5-FU ChT
Placebo + cisplatin and 5-FU ChT
First-line treatment
Gastrointestinal Cancers
Oesophageal or gastroesophageal carcinoma
HER2- GEJ PD-L1 (squamous cell) CPS ≥10
KEYNOTE-590
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Nab-sirolimus
-
Single arm (Phase II)
Efficacy in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
Sarcoma
Perivascular epithelioid
-
AMPECT
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Pembrolizumab
-
Placebo
Adjuvant treatment of RCC for patients with increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
Genitourinary Cancers
Renal cell cancer
-
KEYNOTE-564
A
ADJUSTMENTS
FINAL SCORE
F1
1
Belzutifan
-
Single arm (Phase II)
For adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery
Genitourinary Cancers
von Hippel-Lindau disease-associated Renal Cell Carcinoma
-
MK-6482
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
FOLFOX (folinic acid, fluorouracil, oxaliplatin)
-
Symptomatic care
Second-line treatment of advanced biliary tract cancer
Gastrointestinal Cancers
Biliary tract cancer
-
ABC-06
1
PRELIMINARY SCORE
OS
8
ADJUSTMENTS
FINAL SCORE
F1
5
Tebentafusp
-
Investigator Choice (either dacarbazine, ipilimumab or pembrolizumab)
Treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma
Melanoma
Uveal melanoma
HLA-A*0201positive
IMCgp100-202
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Treatment Setting
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
esmo.mcbs.table.heading.visualisation
esmo.mcbs.table.heading.visualisation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.